Doravirine
Based on 14 publication(s) in Google Scholar
Doravirine (MK-1439) is a highly specific HIV-1 nonnucleoside reverse transcriptase inhibitor with IC50s of 4.5 nM, 5.5 nM and 6.1 nM against the wild type and K103N and Y181C reverse transcriptase mutants, respectively.
For research use only. We do not sell to patients.
- Purity: 99.79%
- CAS No.: 1338225-97-0
- Formula: C17H11ClF3N5O3
- Molecular Weight:425.75
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
FDA-Approved Drug Library
HY-L022
-
Antiviral Compound Library
HY-L027
-
Drug Repurposing Compound Library
HY-L035
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
Orally Active Compound Library
HY-L061
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Drug-Induced Liver Injury (DILI) Compound Library
HY-L076
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
EMA-Approved Drug Library
HY-L116
-
Human Metabolite Library
HY-L123
-
Mitochondrial Toxicity Compound Library
HY-L155
-
Highly Selective Inhibitors Library
HY-L158
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Classic FDA-Approved Drug Library
HY-L261
Publications Citing Use of MedChemExpress (MCE) Doravirine
More- Sci Adv. 2023 Jul 14;9(28):eadg2955. [Abstract]
- J Photochem Photobiol A Chem. 2025 Nov 15;473:116930.
- Molecules. 2023 Mar 30;28(7):3103. [Abstract]
- Int J Antimicrob Agents. 2023 Mar;61(3):106737. [Abstract]
- Int J Antimicrob Agents. 2019 Dec;54(6):814-819. [Abstract]
- J Infect Dis. 2024 Jun 14;229(6):1796-1802. [Abstract]
- J Antimicrob Chemother. 2024 Feb 1;79(2):370-374. [Abstract]
- J Antimicrob Chemother. 2021 Aug 12;76(9):2364-2367. [Abstract]
- J Antimicrob Chemother. 2021 Jan 1;76(1):130-134. [Abstract]
- Viruses. 2021 Jan 18;13(1):131. [Abstract]
- Toxicol Lett. 2025 Apr:406:31-37. [Abstract]
- J Chromatogr B Analyt Technol Biomed Life Sci. 2025 Dec 15:1267:124803. [Abstract]
- bioRxiv. 2026 Jun 10:2026.06.08.730881. [Abstract]
- Preprints. 2024 Aug 30.
Biological Activity
|
HIV-1 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MT4 | CC50 |
>293 μM
Compound: DOR
|
Cytotoxicity against human MT4 cells
Cytotoxicity against human MT4 cells
|
[PMID: 35061384] |
| MT4 | CC50 |
>294 μM
Compound: 6; DOR
|
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability after 5 days by MTT assay
|
[PMID: 30606670] |
| MT4 | CC50 |
>294 μM
Compound: DOR
|
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
Cytotoxicity against mock-infected human MT4 cells assessed as reduction in cell viability measured after 5 days by MTT assay
|
[PMID: 34496571] |
| MT4 | CC50 |
>294 μM
Compound: DOR
|
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction in cell viability by MTT assay
|
[PMID: 38613773] |
| MT4 | CC50 |
293.24 μM
Compound: DOR
|
Cytotoxicity against human MT4 cells assessed as reduction on cell growth by MTT assay
Cytotoxicity against human MT4 cells assessed as reduction on cell growth by MTT assay
|
[PMID: 35797898] |
Selectivity and cytotoxicity studies confirmed that Doravirine is a highly specific nonnucleoside reverse transcriptase inhibitors with minimum off-target activities. In the presence of 50% normal human serum (NHS), Doravirine shows excellent potency in suppressing the replication of WT virus, with a 95% effective concentration (EC95) of 20 nM, as well as K103N, Y181C, and K103N/Y181C mutant viruses with EC9595 of 43, 27, and 55 nM, respectively. Doravirine exhibits similar antiviral activities against 10 different HIV-1 subtype viruses (a total of 93 viruses)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 1338225-97-0
-
Appearance Solid
-
Molecular Weight 425.75
-
Formula C17H11ClF3N5O3
-
Color White to off-white
-
SMILES
N#CC1=CC(OC2=C(C(F)(F)F)C=CN(CC(N3C)=NNC3=O)C2=O)=CC(Cl)=C1
-
Synonyms
MK-1439
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Sci Adv
GRL-142 binds to and impairs HIV-1 integrase nuclear localization signal and potently suppresses highly INSTI-resistant HIV-1 variants. [Abstract]2023 Jul 14;9(28):eadg2955. PMID: 37436982 -
-
Molecules
2023 Mar 30;28(7):3103. PMID: 37049868 -
Int J Antimicrob Agents
Residual phenotypic susceptibility to doravirine in multidrug resistant HIV-1 from subjects enrolled in the PRESTIGIO Registry. [Abstract]2023 Mar;61(3):106737. PMID: 36708743 -
Int J Antimicrob Agents
2019 Dec;54(6):814-819. PMID: 31479744 -
J Infect Dis
Prevalence and phenotypic susceptibility to doravirine of the HIV-1 reverse transcriptase V106I polymorphism in B and non-B subtypes. [Abstract]2024 Jun 14;229(6):1796-1802. PMID: 38206187 -
J Antimicrob Chemother
Variable antiviral activity of islatravir against M184I/V mutant HIV-1 selected during antiretroviral therapy. [Abstract]2024 Feb 1;79(2):370-374. PMID: 38153245 -
J Antimicrob Chemother
Placental transfer of doravirine, a recent HIV-1 NNRTI in the ex vivo human cotyledon perfusion model. [Abstract]2021 Aug 12;76(9):2364-2367. PMID: 34151361 -
J Antimicrob Chemother
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations. [Abstract]2021 Jan 1;76(1):130-134. PMID: 32974670 -
Viruses
Analysis and Molecular Determinants of HIV RNase H Cleavage Specificity at the PPT/U3 Junction. [Abstract]2021 Jan 18;13(1):131. PMID: 33477685 -
Toxicol Lett
Discovery of non-steroidal aldo-keto reductase 1D1 inhibitors through automated screening and in vitro evaluation. [Abstract]2025 Apr:406:31-37. PMID: 39988211 -
J Chromatogr B Analyt Technol Biomed Life Sci
Development, validation and clinical implementation of a HPLC-MS/MS method for the simultaneous quantification of bictegravir, emtricitabine, doravirine, cabotegravir, lenacapavir, fostemsavir, tenofovir alafenamide and the corresponding metabolites temsavir and tenofovir, in human plasma. [Abstract]2025 Dec 15:1267:124803. PMID: 41072339 -
bioRxiv
Structural and Mechanistic Basis of F227C-Mediated Hypersusceptibility to Islatravir in HIV-1 Reverse Transcriptase. [Abstract]2026 Jun 10:2026.06.08.730881. PMID: 42327331 -
Solvent & Solubility
DMSO : 100 mg/mL (234.88 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.87 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lai MT et al. In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor. Antimicrob Agents Chemother. 2014;58(3):1652-63. [Content Brief]
[2]. Anderson MS et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20(4):397-405. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3488 mL | 11.7440 mL | 23.4880 mL | 58.7199 mL |
| 5 mM | 0.4698 mL | 2.3488 mL | 4.6976 mL | 11.7440 mL | |
| 10 mM | 0.2349 mL | 1.1744 mL | 2.3488 mL | 5.8720 mL | |
| 15 mM | 0.1566 mL | 0.7829 mL | 1.5659 mL | 3.9147 mL | |
| 20 mM | 0.1174 mL | 0.5872 mL | 1.1744 mL | 2.9360 mL | |
| 25 mM | 0.0940 mL | 0.4698 mL | 0.9395 mL | 2.3488 mL | |
| 30 mM | 0.0783 mL | 0.3915 mL | 0.7829 mL | 1.9573 mL | |
| 40 mM | 0.0587 mL | 0.2936 mL | 0.5872 mL | 1.4680 mL | |
| 50 mM | 0.0470 mL | 0.2349 mL | 0.4698 mL | 1.1744 mL | |
| 60 mM | 0.0391 mL | 0.1957 mL | 0.3915 mL | 0.9787 mL | |
| 80 mM | 0.0294 mL | 0.1468 mL | 0.2936 mL | 0.7340 mL | |
| 100 mM | 0.0235 mL | 0.1174 mL | 0.2349 mL | 0.5872 mL |
Doravirine Related Classifications
HY-16767 Related Classifications
Powered by Bioz